Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Tryptamine Therapeutics ( (AU:TYP) ).
Tryptamine Therapeutics Limited announced a change in the director’s interest, specifically concerning Chris Ntoumenopoulos. The update reflects a lapse in director options that were incapable of meeting vesting conditions, resulting in a reduction in the number of options held. This change could potentially impact the company’s governance dynamics and influence investor perceptions.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the biotechnology industry, focusing primarily on therapeutic solutions. It is involved in developing advanced treatment options and has a significant presence in the market for innovative medical therapies.
YTD Price Performance: -7.50%
Average Trading Volume: 4,025,654
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$47.23M
Learn more about TYP stock on TipRanks’ Stock Analysis page.
